Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.44 |
| ▸ | HTR2A | P28223 | 3/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 4/20 | 0.34 |
| ▸ | CCND1 | P24385 | 4/20 | 0.34 |
| ▸ | HTR6 | P50406 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1981671 | 0.91 | HTR2C (0.39) | HTR2CHTR2APARP1CDK4CCND1 | |
| SCHEMBL12597616 | 0.86 | HTR2C (0.36) | HTR2CHTR2APARP1HTR6ALDH1A1 | |
| SCHEMBL12598095 | 0.86 | HTR2C (0.36) | HTR2CHTR2APARP1HTR6P2RX7 | |
| SCHEMBL12597615 | 0.83 | HTR2C (0.35) | HTR2CHTR2APARP1HTR6ALDH1A1 | |
| SCHEMBL337413 | 0.81 | HTR2C (0.68) | HTR2CHTR2AHTR6 | |
| SCHEMBL913801 | 0.78 | MPO (0.44) | HTR2CHTR2APARP1HTR6ALDH1A1 | |
| SCHEMBL30672847 | 0.77 | HTR2C (0.42) | HTR2CHTR2APARP1 | |
| SCHEMBL14909548 | 0.77 | HTR2C (0.42) | HTR2CHTR2APARP1 | |
| SCHEMBL12597857 | 0.74 | CNR1 (0.35) | CYP3A4P2RX7 | |
| SCHEMBL14671387 | 0.74 | HTR2C (0.38) | HTR2CHTR2APARP1CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509977-B1 | NOVEL CATIONIC 4-AMINOINDOLES, DYE COMPOSITION COMPRISING A CATIONIC 4-AMINOINDOLE, PROCESSES THEREFOR AND USES THEREOF | OREAL (FR) | 2014-03-26 | — | — | EP | claimed |
| US-20130025618-A1 | NOVEL CATIONIC 4-AMINOINDOLES, DYE COMPOSITION COMPRISING A CATIONIC 4-AMINOINDOLE, PROCESSES THEREFOR AND USES THEREOF | L'OREAL (FR) | 2013-01-31 | — | — | US | claimed |
| WO-2011069952-A1 | NOVEL CATIONIC 4-AMINOINDOLES, DYE COMPOSITION COMPRISING A CATIONIC 4-AMINOINDOLE, PROCESSES THEREFOR AND USES THEREOF | L'OREAL (FR) | 2011-06-16 | — | — | WO | claimed |
| EP-2509977-B1 | NOVEL CATIONIC 4-AMINOINDOLES, DYE COMPOSITION COMPRISING A CATIONIC 4-AMINOINDOLE, PROCESSES THEREFOR AND USES THEREOF | OREAL (FR) | 2014-03-26 | — | — | EP | disclosed |
| EP-2509977-B1 | NOVEL CATIONIC 4-AMINOINDOLES, DYE COMPOSITION COMPRISING A CATIONIC 4-AMINOINDOLE, PROCESSES THEREFOR AND USES THEREOF | OREAL (FR) | 2014-03-26 | — | — | EP | disclosed |
| WO-2011069952-A1 | NOVEL CATIONIC 4-AMINOINDOLES, DYE COMPOSITION COMPRISING A CATIONIC 4-AMINOINDOLE, PROCESSES THEREFOR AND USES THEREOF | L'OREAL (FR) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130025618-A1 | NOVEL CATIONIC 4-AMINOINDOLES, DYE COMPOSITION COMPRISING A CATIONIC 4-AMINOINDOLE, PROCESSES THEREFOR AND USES THEREOF | TPH1, TPH2, FARS2 | HTR2C 49/4885HTR2A 267/4885PARP1 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.